Efficacy of infliximab, cyclosporine and tacrolimus on ulcerative colitis
Open Access
- 30 October 2020
- journal article
- review article
- Published by Wolters Kluwer Health in Medicine
- Vol. 99 (44) , e22894
Abstract
Background: Positioning infliximab (IFX), cyclosporine and tacrolimus (TAC) for treating ulcerative colitis (UC) is in great debate. Methods: A literature search identified studies that investigated IFX vs. cyclosporine or IFX vs TAC in UC patients. Short-term remission, short-term, 1-year and 3-year colectomy rate were employed as primary end-points to assess efficacy. Odds ratios (ORs) with 95% confidence intervals (CIs) were analyzed. Results: Overall, 15 studies comprised 596 patients in IFX group and 866 in calcineurin inhibitors group (644 received cyclosporine and 222 received TAC). No significant difference was seen between IFX and calcineurin inhibitors with regard to short-term remission. IFX led to a lower short-term (OR: 0.59, 95% CI: 0.43–0.82, P:.001), 1-year (OR: 0.53, 95% CI: 0.38–0.73, P < .001), 3-year colectomy (OR: 0.41, 95% CI: 0.20–0.84, P:.02) than calcineurin inhibitors. IFX led to a lower short-term (OR: 0.51, 95% CI: 0.36–0.71, P < .001), 1-year (OR: 0.53, 95% CI: 0.37–0.74, P:.003) colectomy and a trend of lower 3-year colectomy (OR: 0.49, 95% CI: 0.22–1.06, P:.07) than cyclosporine while no significant difference was seen between IFX and TAC. Results of network meta-analysis showed that the order was cyclosporine, TAC and IFX from high rate to low with regard to short-term and 1-year colectomy. Conclusion: IFX treatment leads to a lower short-term, 1-year colectomy rate and a trend of lower 3-year colectomy rate in UC patients than cyclosporine while no significant difference is seen between IFX and TAC. TAC may be superior than cyclosporine with regard to efficacy based on indirect comparisons. Randomized trials with fixed protocol are warranted to identify the optimal medical strategy in patients with UC.Keywords
Funding Information
- Hebei Province Key Research and Development Program (19277770D)
- Hebei Province Key Research and Development Program (182777163)
- Foundation of Health and Family Planning Commission of Hebei (20180686)
- Scientific Research Program of Hebei Administration of Traditional Chinese Medicine (2018039)
- Research Fund of Hebei University of Chinese Medicine (KTY2019027)
This publication has 32 references indexed in Scilit:
- Infliximab versus Cyclosporine Treatment for Severe Corticosteroid-Refractory Ulcerative Colitis: A Korean, Retrospective, Single Center StudyGut and Liver, 2015
- NPC1L1 knockout protects against colitis-associated tumorigenesis in miceBMC Cancer, 2015
- Length of hospital stay and associated hospital costs with infliximab versus cyclosporine in severe ulcerative colitisEuropean Journal of Gastroenterology & Hepatology, 2014
- Outcomes of salvage therapy for steroid-refractory acute severe ulcerative colitis: ciclosporin vs. infliximabAlimentary Pharmacology & Therapeutics, 2013
- Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trialThe Lancet, 2012
- Calcineurin inhibitors and immunosuppression – a tale of two isoformsExpert Reviews in Molecular Medicine, 2012
- Infliximab or cyclosporine for acute severe ulcerative colitis: A retrospective analysisJournal of Gastroenterology and Hepatology, 2012
- Infliximab or Cyclosporine as Rescue Therapy in Hospitalized Patients with Steroid-Refractory Ulcerative Colitis: A Retrospective Observational StudyInflammatory Bowel Diseases, 2012
- Epidemiology and clinical characteristics of ulcerative colitis in Chinese population: Experience from a single center in Hong KongJournal of Gastroenterology and Hepatology, 2007
- Cyclosporine in Severe Ulcerative Colitis Refractory to Steroid TherapyNew England Journal of Medicine, 1994